Pediatrix Medical Group (MD) said Monday it has appointed Executive Chair Mark Ordan as chief executive officer.
Ordan succeeds James Swift, the company said.
Pediatrix also said it expects its 2024 adjusted earnings before interest, taxes, depreciation, and amortization to reach or exceed the high end of its $205 million-to-$215 million guidance range.
Shares of Pediatrix were up 2% during recent premarket activity.
Price: 12.70, Change: +0.26, Percent Change: +2.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.